Colorectal Cancer

Younger patients with early-onset CRC, especially men and racial and ethnic minority groups in urban areas, face a higher risk of cardiovascular death.

Education on colorectal cancer symptoms and screening can help to prevent advancing disease in a cancer that is seeing increased incidence in younger adults.

FIT-DNA modestly improved CRC screening in CHCs, but uptake and follow-up colonoscopy rates remained low.

Behavioral text nudges outperformed nurse calls, boosting FIT completion by 9 percentage points at an FQHC while saving staff time.

Young-onset CRC mortality rose over 3 decades in the US, largely among adults with lower educational attainment, widening socioeconomic gaps.

Housing and transportation barriers were linked to lower CRC screening rates, especially among adults aged 50 to 64.

Repeated at-home stool DNA screening shows higher real-world adherence than colonoscopy, boosting early colorectal cancer detection and cutting deaths over 10 years.

Less than half of US adults aged 45 to 49 years were up to date on colorectal cancer (CRC) screening in 2023, suggesting that age group–specific interventions may improve CRC screening in the US.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

Racial and geographic CRC disparities described in a recent report highlight the need for urgent research and prevention efforts nationwide.

The rise in CRC in adults younger than 65 underscores the need for early screening and prevention efforts.

These new data highlight CRC screening gaps, as well as disparities in incidence and survival.

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

Experts underscored that educating clinicians and the public about red flag CRC symptoms could facilitate earlier screening, diagnosis, and treatment.

Patients with psychiatric disorders had higher CRC risk but no increase in CRC-specific mortality.

Young adults with metastatic CRC (mCRC) and low socioeconomic status (SES) face higher 3-year mortality, whereas race was not independently linked with survival.

Amivantamab-vmjw combined with FOLFOX/FOLFIRI delivers encouraging response rates, durable benefit, and manageable safety.

These results were presented during the press briefing ahead of the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

A study shows falling CRLM incidence and improved survival for synchronous disease, with persistent gaps for metachronous metastases.

From cutting-edge AI detection tools to rising incidence in younger adults and threats to free screenings, 2025 brought major shifts in the struggle against colorectal cancer.

High response rates, strong R0 resection, and low severe adverse events with neoadjuvant therapy plus immunotherapy were identified in a rectal cancer study.

From immunotherapy breakthroughs to early-stage scientific advances shaping the next generation of cancer care, these were the top oncology stories from AACR.

A low-energy total diet replacement program before colorectal cancer surgery helped patients lose weight safely, improved certain symptoms, and showed cost-effectiveness.